Johnson & Johnson's genetically-engineered platelet-derived growthfactor Regranex (becaplermin 0.01%) has been launched in the USA, its first market, for the treatment of diabetic foot ulcers. Regranex was approved by the US Food and Drug Administration at the end of last year (Marketletter December 22, 1997).
A spokeswoman for the company said that the average wholesale price for Regranex 15g is $378. The product has also been filed for approval in Europe, Canada, Latin America, Southeast Asia, South Africa and Australia, she said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze